Roche Australia - Media Release
Roche encourages greater participation in local oncology clinical trials and broader access to comprehensive genomic profiling through new public-private partnership consortium with the Australian Government, research, academia and not-for-profit sectors
SYDNEY, 17 March 2022 – Roche Australia, in partnership with the Australian Federal Government, Omico, and other partners, today announced an agreement to jointly fund an important new initiative aimed at improving access to clinical trials for Australians diagnosed with cancer. Through Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPECT), thousands of eligible cancer patients are expected to gain access to comprehensive genomic profiling (CGP), enabling more efficient clinical trial screening and matching to the most appropriate trial.